Superior Quality PT141 Powder For Lncrease Libido CAS:189691-06-3

    What Is PT-141? A Compound Born from Serendipity

    Most breakthroughs in pharmacology arrive not through deliberate pursuit but through unexpected observation. PT-141-known chemically as bremelanotide-is precisely such a discovery. Its origin story begins not in sexual medicine but in a University of Arizona laboratory during the 1980s, where researchers were developing Melanotan II, a synthetic peptide designed to stimulate skin pigmentation without ultraviolet exposure. The goal was a "universal suntan" compound.

    During early clinical trials, male participants reported something the investigators had not anticipated: spontaneous, robust erections accompanied by a marked increase in sexual thoughts. This serendipitous observation-a side effect that proved more clinically significant than the intended effect-prompted Palatin Technologies to isolate and refine the specific melanocortin receptor agonist responsible.

    PT-141 is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). Its molecular architecture is defined by the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a molecular formula of C₅₀H₆₈N₁₄O₁₀ and a molecular weight of approximately 1025 Da. The peptide incorporates a cyclic lactam bridge between aspartic acid and lysine side chains, which constrains its three-dimensional conformation and confers significant metabolic stability. A D-phenylalanine residue at position seven enhances receptor affinity, while the conserved His-Phe-Arg-Trp (HFRW) core motif-shared with α-MSH and Melanotan II-serves as the pharmacophore for melanocortin receptor binding.

    What distinguishes PT-141 from its parent compound is deliberate receptor selectivity. Whereas Melanotan II retains substantial activity at MC1R (the receptor responsible for melanogenesis in skin), PT-141 was engineered to reduce melanotropic effects while preserving-and in some respects enhancing-its affinity for MC3R and MC4R, the central nervous system receptors most directly implicated in sexual arousal and motivation. PT-141 exhibits an EC₅₀ of 0.2 nM at MC4R and 0.4 nM at MC3R in cAMP accumulation assays, whereas Melanotan II displays Ki values of 6.6 nM at MC4R.

PT-141 received FDA approval in June 2019 under the brand name Vyleesi, specifically for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women-marking the first injectable drug ever approved for this condition. However, its applications have since expanded substantially through off-label use and clinical investigation.

 

    Melanocortin Receptor Binding Profile

    The melanocortin receptor family comprises five subtypes (MC1R through MC5R), each with distinct tissue distributions and physiological functions. PT-141 functions as a non-selective melanocortin receptor agonist with the following rank order of potency: MC1R, MC4R, MC3R, MC5R, MC2R. For purposes of sexual function, the clinically relevant targets are MC4R (Ki approximately 0.6 nM) and MC3R (Ki approximately 2.1 nM).

    MC4R is expressed extensively in hypothalamic and limbic brain regions, including the paraventricular nucleus and the medial preoptic area-circuits that serve as the central command centers for sexual motivation, arousal, and reward. PT-141\u2019s activation of MC4R triggers a downstream signaling cascade that enhances dopaminergic tone in the mesolimbic pathway. Specifically, MC4R-expressing neurons in the hypothalamus project to dopaminergic nuclei, increasing dopamine release in the nucleus accumbens-the brain's primary reward and motivation hub.

    Central Mechanism vs. Peripheral Agents

    This central mechanism fundamentally distinguishes PT-141 from conventional sexual health medications. PDE5 inhibitors such as sildenafil (Viagra) and tadalafil (Cialis) act peripherally by inhibiting an enzyme that degrades cyclic GMP in vascular smooth muscle, resulting in enhanced blood flow to the genitalia. These drugs do not create desire; they merely facilitate the vascular response to desire that already exists. For individuals whose core issue is absent libido rather than impaired blood flow, PDE5 inhibitors often prove disappointing.

    PT-141 operates upstream of this process. By directly activating the neurological circuits that generate sexual motivation, the peptide can produce the urge itself-not merely facilitate the physical response to a pre-existing urge. This distinction is not subtle; it represents a fundamentally different therapeutic category: neuropharmacological modulation of desire rather than vasodilation.

    Some research has characterized PT-141\u2019s effect profile as enhancing "wanting" rather than "liking"-the motivational drive toward sexual engagement rather than the hedonic experience of pleasure itself. This distinction emerges from the observation that MC4R activation boosts anticipatory reward signaling without necessarily altering consummatory experience. In practical terms, users report feeling more spontaneously receptive to sexual stimuli, experiencing sexual thoughts and fantasies more readily, and noticing reduced psychological barriers to intimacy.

    Physicochemical Properties

    As a lyophilized powder stored before reconstitution, superior quality PT-141 presents as a solid white to off-white material. For short-term storage (days to weeks), the powder should be kept at 0 to 4 degrees Celsius in a dry, dark environment; for long-term storage (months to years), temperatures of minus 20 degrees Celsius are recommended. The peptide is soluble in water for reconstitution with bacteriostatic water or sterile saline, with acidified solutions (pH 4-5) typically improving stability. Once reconstituted, PT-141 solutions should be refrigerated and used within 28 days to prevent peptide degradation.

    Peptide purity constitutes a critical quality parameter. Pharmaceutical-grade PT-141 for clinical use typically exceeds 99% purity by HPLC analysis, with endotoxin levels below 1 EU/mg. Research-grade material intended for laboratory investigation generally maintains purity above 98%. The powder form allows for precise weight-based dosing, which is essential given the compound's steep dose-response curve and narrow therapeutic window.

    FDA-Approved Indication: Female HSDD

    The primary regulatory approval for PT-141 targets premenopausal women with acquired, generalized hypoactive sexual desire disorder. HSDD is characterized by persistent low sexual desire that causes marked personal distress and cannot be attributed to another medical condition, psychiatric disorder, relationship difficulties, or medication side effects.

    Phase III clinical trials demonstrated statistically significant improvements in sexual desire scores and reductions in distress compared to placebo, confirming reproducible, modest, yet clinically relevant efficacy. The on-demand administration schedule-use only when sexual activity is anticipated-provides a distinct advantage over daily medications. Key trial data showed that a significantly greater proportion of women receiving PT-141 reported increases in satisfying sexual events compared to placebo.

    Off-Label Applications in Men

    Though PT-141 is not FDA-approved for male indications, substantial clinical and anecdotal evidence supports its off-label use for men with low libido and erectile dysfunction, particularly those who respond inadequately to PDE5 inhibitors. In one survey of off-label users, 91 percent of men experienced improvements in overall sexual function, with 100 percent of those reporting low sexual desire or anxiety around sex noting improvement following PT-141 administration.

    The utility in men stems from the same central mechanism that benefits women. For individuals with desire-related erectile dysfunction-where the physical capacity is intact but the neurological drive is absent-PT-141 offers a solution that no vasodilator can provide. Additionally, PT-141 has shown efficacy in men with PDE5-inhibitor non-response, a population estimated to include 30 to 40 percent of ED patients. Since PT-141 operates through a completely distinct pharmacological pathway (melanocortin agonism versus PDE5 inhibition), the two mechanisms can be additive or even synergistic. Some clinical protocols combine PT-141 with low-dose PDE5 inhibitors for men with severe multifactorial sexual dysfunction.

    Benefits for Both Sexes

    Restoration of Genuine Desire. Unlike treatments that merely enable physical performance, PT-141 targets the subjective experience of wanting. Users consistently describe the resulting arousal as feeling qualitatively closer to natural, organic desire than to the mechanically facilitated response produced by vasodilators.

    On-Demand Flexibility. The peptide is not a daily medication. It requires no loading phase, no chronic accumulation, no hormonal suppression, and no ongoing commitment. Use it when you intend to be sexually active; skip it otherwise. The onset of effects typically begins within 45 to 60 minutes of subcutaneous administration, with peak effects around 90 minutes and total duration ranging from 6 to 12 hours.

    Hormone Independence. PT-141 does not alter testosterone, estrogen, or progesterone levels. It modulates sexual function through central neurochemical pathways entirely separate from the hypothalamic-pituitary-gonadal axis. For individuals who cannot or prefer not to undergo hormone replacement therapy, this offers a uniquely non-hormonal option.

    Efficacy in PDE5 Non-Responders. For patients who have exhausted conventional options without satisfaction, PT-141 represents an entirely new avenue of intervention addressing a different underlying physiology.

    Dual Indication Across Sexes. One of very few pharmacologic agents that demonstrates clinically meaningful libido enhancement in both men and women, PT-141 addresses a significant gap in sexual medicine where most treatments are sex-specific.

    Improved Psychosexual Experience. By reducing the psychological distress associated with absent desire, the peptide can help break cycles of performance anxiety and expectation failure that exacerbate underlying dysfunction.

    Approved FDA Dosing

    The regulatory-approved Vyleesi regimen consists of a 1.75 mg subcutaneous injection administered at least 45 minutes prior to anticipated sexual activity. Patients are explicitly advised not to exceed one dose within any 24-hour period and no more than eight doses per calendar month.

    Off-Label Dosing for Research and Clinical Investigation

    In off-label and research contexts, dosing is often individualized based on response and tolerability. A common starting dose for men is 0.5 mg subcutaneously, with gradual titration upward to 1.0 mg or, in some cases, 2.0 mg depending on effect and side effect burden. Starting low dramatically reduces the incidence and severity of nausea, the most common adverse effect.

    Subcutaneous injection is the standard route of administration. The injection is typically delivered into the subcutaneous tissue of the abdomen or thigh using an insulin syringe. The autoinjector device used for Vyleesi administration provides a standardized delivery system, but off-label use often involves manual syringe administration of reconstituted powder.

    Intranasal administration is also described in the literature, though with less consistent bioavailability and absorption. Research protocols employing intranasal PT-141 typically formulate concentrations ranging from 1 mg/mL to 10 mg/mL, with patients dosing 1 to 4 sprays approximately 30 to 60 minutes before anticipated sexual activity. Two sprays deliver approximately 133 mcg of PT-141; four sprays deliver approximately 267 mcg.

    Cycle Considerations

    Unlike anabolic steroids or hormonal modulators, PT-141 does not require classic "cycling" in the sense of planned on-off periods to avoid hypothalamic-pituitary-gonadal axis suppression. However, tolerance development is well-documented. With repeated use, particularly at higher doses and frequencies, the desired libido-enhancing effect can diminish. Clinical experience suggests that tolerance typically emerges after approximately eight to twelve doses, though individual variation is substantial.

    For individuals who experience tolerance, a washout period of one to two weeks reliably restores full responsiveness. This has practical implications for cycle design. A common protocol involves using PT-141 once weekly for approximately eight to ten weeks, followed by a two-week holiday. Alternatively, for on-demand use without regular frequency, tolerance rarely becomes an issue because exposures are spaced sufficiently apart.

    Another cycling consideration is the management of nausea and other acute side effects. Some users report that side effects diminish with repeated administration, suggesting partial adaptation. This has led some clinicians to recommend a "test dose" of 0.5 mg before initiating any protocol involving higher doses-allowing the individual to establish their side effect profile and tolerance trajectory without committing to a full therapeutic dose.

    Terminal Half-Life

    The plasma elimination half-life of PT-141 following subcutaneous administration is approximately 2.7 hours. This relatively short half-life has two important practical implications:

    First, the window for therapeutic effect is well-defined. Drug concentration peaks approximately 60 to 90 minutes post-injection and remains above the minimum effective concentration for roughly 6 to 12 hours. Patients should time administration accordingly.

    Second, the compound clears relatively quickly, meaning that side effects-most notably nausea-are typically self-limited. The peak incidence of nausea occurs in the first two hours after injection and generally resolves without intervention within three to four hours.

    Absorption and Bioavailability

    Following subcutaneous administration, bioavailability is high, approaching 100 percent. The drug bypasses hepatic first-pass metabolism entirely, which is essential because PT-141 is not orally bioavailable-it is a peptide that would be degraded by digestive enzymes if ingested orally.

    Intranasal administration provides more variable absorption. While the nasal mucosa offers a route that also bypasses gastrointestinal degradation, absorption efficiency depends on multiple factors including mucosal health, technique, and formulation. Bioavailability estimates for intranasal PT-141 range from 30 to 60 percent of subcutaneous exposure, though direct comparative data are limited.

    Metabolism and Elimination

    PT-141 is metabolized by peptidases into smaller peptide fragments and individual amino acids, which enter general amino acid pools. The compound is not metabolized by cytochrome P450 enzymes, meaning that drug-drug interactions through this pathway are not a concern. However, co-administration with other melanocortin receptor agonists or antagonists could theoretically modulate effects.

    The primary metabolites have no intrinsic pharmacologic activity at melanocortin receptors. Excretion is renal, with the majority of metabolic products eliminated in urine within 24 to 48 hours.

    Frequent Adverse Effects

    Nausea is the most common side effect, occurring in approximately 39 to 40 percent of clinical trial participants. The incidence is dose-dependent: higher doses produce more frequent and more severe nausea. The mechanism is believed to involve MC4R activation in the area postrema, a circumventricular region of the brainstem that regulates emesis.

    Practical management strategies for nausea include starting with a low dose (0.5 mg) and only titrating upward after tolerance is established, administering an antiemetic (such as ondansetron) 30 minutes before PT-141 injection, and injecting on a relatively empty stomach.

    Transient Hypertension

    Perhaps the most clinically significant safety consideration is the potential for transient blood pressure elevation. Studies have documented average increases of approximately 2 to 3 mmHg in systolic blood pressure; however, some individuals may experience more substantial elevations. Heart rate may concomitantly decrease.

    Given the cardiovascular system's integral role in sexual response-including the hemodynamic changes that accompany arousal-this effect warrants monitoring. PT-141 is contraindicated in individuals with uncontrolled hypertension or significant cardiovascular disease. Blood pressure should be measured before administration in any patient with cardiovascular risk factors.

    Dermatological Effects

    As a compound derived from the melanocortin family with residual MC1R activity, PT-141 can produce skin pigmentation changes with extended use. Increased melanin deposition, darkening of pre-existing moles or freckles, and generalized hyperpigmentation have been documented. These changes typically reverse following discontinuation but may require weeks to months for complete resolution.

    A crucial clarification must be made regarding "post-cycle therapy" (PCT) for PT-141. In the anabolic steroid and hormonal modulation communities, PCT refers to a structured pharmacologic intervention designed to restore endogenous hormone production after exogenous suppression. This usually involves selective estrogen receptor modulators (such as tamoxifen or clomiphene) or human chorionic gonadotropin.

    PT-141 does not require PCT. It does not suppress endogenous hormones. There is no negative feedback loop affecting testosterone, estrogen, or progesterone production. No hypothalamic-pituitary-gonadal axis inhibition occurs. The compound acts on melanocortin receptors in the central nervous system, not on steroidogenic pathways or gonadotropin secretion.

    The term "post-cycle" as applied to PT-141 refers instead to a different phenomenon: tolerance reversal. After a period of frequent use (e.g., weekly administration for eight to twelve weeks), some individuals notice diminishing effects. Taking a one-to-two-week washout period restores sensitivity to the peptide. This does not constitute PCT in the conventional sense but rather a simple drug holiday.

    Some clinicians recommend "post-cycle" considerations that include monitoring for rebound effects. Does libido drop below baseline after discontinuing PT-141? Current evidence suggests the answer is no. Because PT-141 does not alter baseline neurochemistry but rather temporarily enhances a specific signaling pathway, cessation simply returns the individual to their pre-treatment state. There is no withdrawal syndrome, no hormonal crash, and no overshoot below baseline.

    However, psychological rebound is worth noting. Individuals who have become accustomed to the enhanced libido produced by PT-141 may perceive their natural baseline as deficient by comparison. This perceptual effect-not a true pharmacologic withdrawal-can lead to a subjective sense of lower libido post-discontinuation. Education and expectation management help mitigate this.

Trade names	Bremelanotide, Vyleesi, Rekynda, bremelanotide acetate
CAS	189691-06-3
Molar mass	1025.182
Formula	C50H68N14O10
Purity	Above 98%
Apprarance	White crystalline powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    PT-141 represents a genuine paradigm shift in sexual medicine: the first neuropharmacologic agent that directly targets the central mechanisms of desire rather than the peripheral mechanics of performance. Derived from an accidental observation during tanning peptide research, refined through rational drug design to optimize receptor selectivity, and clinically validated through rigorous Phase III trials, this synthetic cyclic heptapeptide occupies a unique pharmacologic niche.

    For individuals whose sexual dysfunction stems from absent or diminished libido-regardless of whether hormonal profiles, vascular function, and physical capacity are intact-PT-141 offers something no PDE5 inhibitor can provide: the restoration of wanting itself. Its on-demand administration, rapid onset, and self-limited duration of effect align well with the spontaneous nature of sexual activity. Its side effect profile, while significant, is well-characterized and manageable with appropriate dosing strategies and monitoring.

    Superior quality PT-141 powder, when properly sourced, stored, reconstituted, and administered, provides a precision tool for addressing low libido at its neurological source. It is not a panacea, nor is it indicated for every individual with sexual concerns. But for the select population whose primary deficit lies in central motivation rather than peripheral function, this compound may make the critical difference between resignation and restoration.

Hot Tags: superior quality pt141 powder for lncrease libido cas:189691-06-3, China superior quality pt141 powder for lncrease libido cas:189691-06-3 manufacturers, suppliers, factory